{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=55",
    "query": {
      "intervention": "Pharmacodynamics",
      "page": 55
    },
    "page_size": 10
  },
  "pagination": {
    "page": 55,
    "page_size": 10,
    "total_count": 3448,
    "total_pages": 345,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=56&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pharmacodynamics&page=54&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:30:28.410Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02075034",
      "title": "Three Dosing Schedules of Oral Rigosertib in MDS Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "rigosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Traws Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-05",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075034"
    },
    {
      "nct_id": "NCT02377427",
      "title": "Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 36,
      "start_date": "2015-08-25",
      "completion_date": "2018-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Oklahoma City, Oklahoma • Medford, Oregon + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02377427"
    },
    {
      "nct_id": "NCT05118841",
      "title": "Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ZX-4081",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nanjing Zenshine Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-01-03",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 1,
      "location_summary": "Huntersville, North Carolina",
      "locations": [
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118841"
    },
    {
      "nct_id": "NCT03379740",
      "title": "Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaping",
        "Nicotine Absorption"
      ],
      "interventions": [
        {
          "name": "E-cigarette",
          "type": "OTHER"
        },
        {
          "name": "P4M3-1.7%",
          "type": "OTHER"
        },
        {
          "name": "P4M3-1.7%LA",
          "type": "OTHER"
        },
        {
          "name": "P4M3-3%LA",
          "type": "OTHER"
        },
        {
          "name": "P4M3-4%LA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Philip Morris Products S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-07-11",
      "completion_date": "2017-12-01",
      "has_results": true,
      "last_update_posted_date": "2019-11-22",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 1,
      "location_summary": "High Point, North Carolina",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03379740"
    },
    {
      "nct_id": "NCT02337686",
      "title": "Pembrolizumab in Treating Patients With Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Recurrent Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-04-28",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02337686"
    },
    {
      "nct_id": "NCT02349503",
      "title": "Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Adrenal Hyperplasia"
      ],
      "interventions": [
        {
          "name": "NBI-77860",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2015-02",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-06-11",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Seattle, Washington",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349503"
    },
    {
      "nct_id": "NCT02650973",
      "title": "Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CHS-1701",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coherus Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 122,
      "start_date": "2016-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-08-01",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 4,
      "location_summary": "Cypress, California • Cincinnati, Ohio • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650973"
    },
    {
      "nct_id": "NCT00847886",
      "title": "Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "LX3305",
          "type": "DRUG"
        },
        {
          "name": "LX3305 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2009-02",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2010-06-03",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847886"
    },
    {
      "nct_id": "NCT06944925",
      "title": "A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "BBT002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bambusa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 286,
      "start_date": "2025-05-08",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 3,
      "location_summary": "Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York",
      "locations": [
        {
          "city": "Bowling Green",
          "state": "Kentucky"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06944925"
    },
    {
      "nct_id": "NCT01199718",
      "title": "Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CX-4945",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cylene Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-09",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-06-15",
      "last_synced_at": "2026-11-19T06:30:28.410Z",
      "location_count": 6,
      "location_summary": "Kettering, Ohio • Portland, Oregon • Springfield, Oregon + 3 more",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199718"
    }
  ]
}